Navigation Links
Scarguard Labs, LLC Appoints Richard E. Pino as CFO
Date:1/14/2009

GREAT NECK, N.Y., Jan. 14 /PRNewswire/ -- Scarguard Labs, LLC, a closely held company specializing in the treatment of scars and other dermatological problems through the use of multi-technology drugs enhanced by a proprietary contact delivery system, announced it has appointed Richard E. Pino as Chief Financial Officer. He will be responsible for the Company's finance, accounting, and treasury functions and will report to Chief Executive Officer, Joel Studin, MD.

Prior to his appointment, Mr. Pino served as Chief Financial Officer / Chief Operating Officer for EcoSys Management LLC, a leader in enterprise project and operations financial management solutions. While there, Mr. Pino was responsible for overall operations: Finance, HR, Legal and Facilities. Previously, Mr. Pino was the Chief Financial Officer for The Relegence Corporation, which became a wholly-owned subsidiary of AOL, a TimeWarner Company during Pino's tenure.

From 2001 through 2005, Pino was the CFO for Frontline Communications International, Inc. where he was responsible for overall operations as well as overseeing outside accounting, tax and legal firms. Prior to 2001, Mr. Pino held various financial positions in of the following industries: Telecom, investment banking and media. He currently serves in a financial capacity on the boards of several non-profit organizations, including The Brooklyn Philharmonic and the Museum of Biblical Art.

Mr. Pino received his BA from St. Francis College in 1990 and his MBA from Adelphi University in 1993.

Speaking of Mr. Pino's appointment, Dr. Studin said, "We couldn't be happier that Richard agreed to join our Company. His experience covers all aspects of the finance, treasury and accounting roles, and includes strategic planning, mergers and acquisitions, all roles that he will fulfill while at Scarguard. He will be a key part of Scarguard's growth as a company."

About Scarguard Labs, LLC.

Scarguard Labs, LLC is a closely held pharmaceutical company specializing in dermatological medications employing an internationally patented delivery system designed to enhance drug effectiveness utilizing a multi-technology approach. Our flagship product, Scarguard, is the most frequently dispensed product for scars in plastic surgery offices since 2001. In addition, it can be found in most pharmacies, drug distributors and major grocery chains throughout the United States. We have multiple topical prescription and non-prescription drugs in the marketplace, or in varying stages of development. For more information, please visit our website at www.scarguard.com

    Company Contact:
    Richard E. Pino
    Chief Financial Officer /Investor Relations
    Scarguard Labs, LLC
    516-482-8050
    Richard@scarguard.com

    Investor Relations:
    John McNamara
    Cameron Associates
    (212) 245-8800 Ext. 205
    john@cameronassoc.com


'/>"/>
SOURCE Scarguard Labs, LLC
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Scarguard Labs, LLC Expands Distribution Reach Through Agreements With McKesson Drugs and Publix Supermarkets
2. Innovatech Labs, Assisting Companies in Adhering to Halogen-Free Manufacturing Standards Aimed at Protecting the Environment
3. ForSight Labs, LLC Announces Formation of Its Third Company, ForSight VISION3, Inc. and Closing of $6 Million in Series A Funding
4. Access MediQuip Appoints Former Priority Healthcare CEO to Chairman of the Board
5. Boehringer Ingelheim Appoints Albert Ros as Executive Vice President of Sales and Marketing for Prescription Medicines
6. ev3 Inc. Appoints Shawn McCormick as New Sr. Vice President and Chief Financial Officer
7. Amira Pharmaceuticals, Inc. Expands its Scientific Advisory Board and Appoints Dr. Paul Anderson, Professor Jerold Chun and Professor Andrew Tager
8. Hillenbrand, Inc. Appoints Jan Santerre Vice President of Lean Business
9. eDiets.com(R) Appoints Kevin N. McGrath as President and CEO
10. Bon Secours Charity Health System Appoints Terence M. O'Brien as Chief Executive Officer
11. Bat Saliva-Based Stroke Drug Disappoints in Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... Austin residents ... the American College of Mohs Surgery and to Dr. Russell Peckham for medical and ... highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... "With 30 ... their specific project," said Christina Austin - CEO of Pixel Film Studios. , ... and all within Final Cut Pro X . Simply select a ProHand generator ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern ... Laude and his M.D from the David Geffen School of Medicine at UCLA. He ... Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program ...
(Date:6/25/2016)... ... ... On Friday, June 10, Van Mitchell, Secretary of the Maryland Department of Health and ... their exemplary accomplishments in worksite health promotion. , The Wellness at Work Awards took ... the BWI Marriott in Linthicum Heights. iHire was one of 42 businesses to receive ...
(Date:6/24/2016)... ... ... A recent article published June 14 on E Online details ... to state that individuals are now more comfortable seeking to undergo not only the ... and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians (BHP) notes ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Research and Markets has announced the addition of ... report to their offering. ... kidney failure, it replaces the function of kidneys by removing ... thus the treatment helps to keep the patient body,s electrolytes ... Increasing number of ESRD patients & substantial healthcare expenditure ...
(Date:6/23/2016)... June 23, 2016 Research and ... Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), ... Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is projected ... CAGR of 6.1% in the forecast period 2016 to ...
(Date:6/23/2016)... -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that ... PCT (procalcitonin) assay as a dedicated testing solution for ... clearance, Roche is the first IVD company in the ... risk assessment and management. PCT is a ... in blood can aid clinicians in assessing the risk ...
Breaking Medicine Technology: